NeoGenomics, Inc. (NEO) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -68.44M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | 429.76M USD | Cost of Goods and Services Sold |
| Research and development | 38.17M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-68.44M | (m) | $429.76M | $38.17M | (m) | (m) |
| 2026-03-31 | $-106.30M | (m) | $424.06M | $36.43M | (m) | (m) |
| 2025-12-31 | $-115.88M | (m) | $413.04M | $37.08M | (m) | (m) |
| 2025-09-30 | $-120.87M | (m) | $400.95M | $35.87M | (m) | (m) |
| 2025-06-30 | $-115.05M | (m) | $386.55M | $34.86M | (m) | (m) |
| 2025-03-31 | $-89.36M | (m) | $374.48M | $33.72M | (m) | (m) |
| 2024-12-31 | $-92.11M | (m) | $370.47M | $31.16M | (m) | (m) |
| 2024-09-30 | $-92.28M | (m) | $363.69M | $30.32M | (m) | (m) |
| 2024-06-30 | $-95.28M | (m) | $360.39M | $27.92M | (m) | (m) |
| 2024-03-31 | $-103.23M | (m) | $355.40M | $27.53M | (m) | (m) |
| 2023-12-31 | $-107.74M | (m) | $347.04M | $27.31M | (m) | (m) |
| 2023-09-30 | $-115.55M | (m) | $340.95M | $26.86M | (m) | (m) |
| 2023-06-30 | $-130.86M | (m) | $331.20M | $28.88M | (m) | (m) |
| 2023-03-31 | $-140.67M | (m) | $325.30M | $30.01M | (m) | (m) |
| 2022-12-31 | $-157.62M | (m) | $321.83M | $30.33M | (m) | (m) |
| 2022-09-30 | $-172.81M | (m) | $320.43M | $32.16M | (m) | (m) |
| 2022-06-30 | $-173.01M | (m) | $314.64M | $32.26M | (m) | (m) |
| 2022-03-31 | $-155.68M | (m) | $302.25M | $27.13M | (m) | (m) |
| 2021-12-31 | $-118.75M | (m) | $297.27M | $21.87M | (m) | (m) |
| 2021-09-30 | $-71.65M | (m) | $285.34M | $15.46M | (m) | (m) |
| 2021-06-30 | $-27.27M | (m) | $282.62M | $10.02M | (m) | (m) |
| 2021-03-31 | $-23.81M | (m) | $272.85M | $8.63M | (m) | (m) |
| 2020-12-31 | $-13.99M | (m) | $258.56M | $8.23M | (m) | (m) |
| 2020-09-30 | $-17.21M | (m) | $246.96M | $8.21M | (m) | (m) |
| 2020-06-30 | $-18.22M | (m) | $229.42M | $8.86M | (m) | (m) |
| 2020-03-31 | $5.17M | (m) | $223.19M | $9.34M | (m) | (m) |
| 2019-12-31 | $13.01M | (m) | $211.99M | $8.49M | (m) | (m) |
| 2019-09-30 | $13.51M | (m) | $194.41M | $6.93M | (m) | (m) |
| 2019-06-30 | $13.77M | (m) | $177.35M | $4.77M | (m) | (m) |
| 2019-03-31 | $10.08M | (m) | $161.82M | $3.25M | (m) | (m) |
| 2018-12-31 | $10.04M | (m) | $149.48M | $3.00M | (m) | (m) |
| 2018-09-30 | $10.34M | (m) | (m) | $3.03M | (m) | (m) |
| 2018-06-30 | $4.36M | (m) | (m) | $3.86M | (m) | (m) |
| 2018-03-31 | $5.41M | (m) | (m) | $3.73M | (m) | (m) |
| 2017-12-31 | $2.32M | (m) | (m) | $3.64M | (m) | (m) |
| 2017-09-30 | $-5.10M | (m) | (m) | $4.01M | (m) | (m) |
| 2017-06-30 | $-340.00K | (m) | (m) | $3.71M | (m) | (m) |
| 2017-03-31 | $537.00K | (m) | (m) | $4.07M | (m) | (m) |
| 2016-12-31 | $2.57M | (m) | (m) | $4.65M | (m) | (m) |
| 2016-09-30 | $293.00K | (m) | (m) | $5.58M | (m) | (m) |
| 2016-06-30 | $-988.00K | (m) | (m) | $5.48M | (m) | (m) |
| 2016-03-31 | $-3.15M | (m) | (m) | $4.97M | (m) | (m) |
| 2015-12-31 | $-5.63M | (m) | (m) | $4.20M | (m) | (m) |
| 2015-09-30 | $900.00K | (m) | (m) | $2.76M | (m) | (m) |
| 2015-06-30 | $712.00K | (m) | (m) | $2.90M | (m) | (m) |
| 2015-03-31 | $1.26M | (m) | (m) | $2.73M | (m) | (m) |
| 2014-12-31 | $2.22M | (m) | (m) | $2.69M | (m) | (m) |
| 2014-09-30 | $2.10M | (m) | (m) | $2.92M | (m) | (m) |
| 2014-06-30 | $3.34M | (m) | (m) | $2.25M | (m) | (m) |
| 2014-03-31 | $3.26M | (m) | (m) | $2.23M | (m) | (m) |
| 2013-12-31 | $3.17M | (m) | (m) | $2.44M | (m) | (m) |
| 2013-09-30 | $2.17M | (m) | (m) | $2.24M | (m) | (m) |
| 2013-06-30 | $321.00K | (m) | (m) | $2.71M | (m) | (m) |
| 2013-03-31 | $655.00K | (m) | (m) | $2.62M | (m) | (m) |
| 2012-12-31 | $1.21M | (m) | (m) | $2.28M | (m) | (m) |
| 2012-09-30 | $1.39M | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | $2.12M | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | $1.16M | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $-409.00K | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-2.96M | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |